Abstract
Current recommendations for the antithrombotic management of patients receiving oral anticoagulation (OAC) who undergo percutaneous coronary intervention with stent implantation (PCI-S) are based on limited and relatively weak data. To broaden and strengthen available evidence, the management and 1-year outcomes of OAC patients who underwent PCI-S and were included in a prospective, multicenter registry from 2003 to 2007 were evaluated. Among the 632 patients receiving OAC, mostly because of atrial fibrillation (58%), who underwent PCI-S, mostly because of acute coronary syndromes (63%), dual-antiplatelet therapy with aspirin and clopidogrel was the most frequently prescribed at discharge (48%), followed by triple therapy with OAC, aspirin, and clopidogrel (32%) and OAC plus aspirin (18%). The choice of antithrombotic therapy largely matched the thromboembolic risk profiles of patients, with the prescription of regimens including OAC predicted by the presence of non-low-risk features. The cumulative 1-year occurrence of major adverse cardiovascular events was as high as 27% and was not significantly different among the 3 treatment groups. Stroke and stent thrombosis were limited to 2% and 3%, respectively, and although no signi...Continue Reading
References
Jun 14, 2005·The American Journal of Cardiology·Antonio MarzocchiAleardo Maresta
Nov 16, 2005·Cardiology·Yuval KonstantinoDavid Hasdai
Jan 3, 2006·Heart·A OudotY Cottin
Feb 3, 2007·European Heart Journal·Pasi P KarjalainenK E Juhani Airaksinen
May 2, 2007·Circulation·Donald E CutlipUNKNOWN Academic Research Consortium
Jul 9, 2008·Annals of Medicine·Andrea RubboliGregory Y H Lip
Nov 8, 2008·Thrombosis and Haemostasis·Andrea Rubboli, Jonathan L Halperin
Dec 10, 2008·The American Journal of Cardiology·Roberta RossiniDominick J Angiolillo
May 20, 2009·Heart·A SambolaP Tornos
Oct 27, 2009·American Heart Journal·Willem Dewilde, Jurriën Ten Berg
Nov 20, 2009·Circulation·Frederick G KushnerUNKNOWN American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Mar 9, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Fei GaoMiao Yu
Sep 30, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·A John CammUNKNOWN ESC Committee for Practice Guidelines
Feb 3, 2011·Chest·Hong-Jin ZhaoWei Zhang
Jul 26, 2011·Thrombosis and Haemostasis·David P FaxonDominick J Angiolillo
Citations
Oct 19, 2012·Thrombosis Journal·Mila MenozziRoberto Grilli
Aug 27, 2013·Heart and Vessels·Soon Yong SuhEak Kyun Shin
Aug 27, 2014·European Heart Journal·Gregory Y H LipJose L Zamorano
Jan 3, 2016·International Journal of Cardiology·Jian LiuYugang Dong
Jan 1, 2016·JACC. Cardiovascular Interventions·Larry R JacksonTracy Y Wang
Jul 3, 2015·Herz·Chao-Feng ChenYi-Zhou Xu
Jun 22, 2015·International Journal of Cardiology·Andrea RubboliGregory Y H Lip
Mar 24, 2015·The American Journal of Cardiology·Fabrizio D'AscenzoFiorenzo Gaita
Sep 11, 2014·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Mohan Mallikarjuna Rao EdupugantiAbdul Hakeem
Aug 29, 2014·Journal of Thrombosis and Thrombolysis·Jung Rae Cho, Dominick J Angiolillo
Jul 9, 2016·Journal of Thrombosis and Thrombolysis·Jonathan RilingerChristoph B Olivier
Aug 23, 2019·Journal of Cardiovascular Electrophysiology·Varunsiri AttiDhanunjaya Lakkireddy
Sep 18, 2018·Coronary Artery Disease·Doosup ShinEun Sun Lee
Nov 9, 2017·Oncotarget·Wengen ZhuKui Hong
May 18, 2018·BioMed Research International·Nayan AgarwalAhmed N Mahmoud
Dec 5, 2018·Frontiers in Pharmacology·Wipharak BunmarkSurakit Nathisuwan
May 21, 2019·International Heart Journal·Xiaofei GaoJunjie Zhang
Oct 21, 2016·Cardiovascular Drugs and Therapy·Lucia BarbieriGiuseppe De Luca
Jun 20, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Ayesha AtherVincent Y See